

## Valneva Supports World Encephalitis Day on February 22, 2017

As the manufacturer and supplier of IXIARO<sup>®</sup> – the only licensed and recommended Japanese encephalitis (JE) vaccine in the US and Europe, Valneva SE is proud to support The Encephalitis Society to raise the awareness of the impact of encephalitis on World Encephalitis Day (WED). Encephalitis, a swelling of the brain, is a devastating condition which affects 500,000 people globally each year.

Valneva offices in Austria, Scotland and Sweden will light up in red on February 22<sup>nd</sup>, 2017 contributing to the “Illuminate Encephalitis” Campaign launched by the Encephalitis Society which will see many iconic landmarks worldwide going red such as the Niagara Falls, the fountain at Trafalgar Square London and the Peace Bridge linking Canada and the USA.

Valneva employees worldwide will be joining the #RED4WED initiative by wearing red World Encephalitis Day t-shirts or other items of red clothing aiming to raise the awareness of Encephalitis.

Christian Taucher, Head of Global Medical Affairs at Valneva commented, “What inspires me to come to work each day is our commitment to protect people from serious harm such as Japanese Encephalitis, the most common encephalitis in Asia. We support the World Encephalitis Day so that those people affected as well as their families, have access to early diagnosis, excellent management of their condition, timely access to rehabilitation and other forms of social support.”

The Encephalitis Society was founded in 1994 and is the only resource of its kind in the world providing direct support and information to individuals and families affected by encephalitis.

More details on the World Encephalitis Day can be found on the Encephalitis Society website, please visit [www.worldencephalitisday.org](http://www.worldencephalitisday.org)

### About Valneva

Valneva is a fully integrated, commercial stage biotech company focused on developing innovative lifesaving vaccines.

The Company seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability.

Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO<sup>®</sup>/JESPECT<sup>®</sup> indicated for the prevention of Japanese encephalitis and DUKORAL<sup>®</sup> indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has proprietary vaccines in development

including candidates against Clostridium difficile and Lyme disease. A variety of partnerships with leading pharmaceutical companies complement the Company's value proposition and include vaccines being developed using Valneva's innovative and validated technology platforms (EB66<sup>®</sup> vaccine production cell line, IC31<sup>®</sup> adjuvant). Valneva is listed on Euronext-Paris and the Vienna stock exchange and has operations in France, Austria, Great Britain, Sweden, Canada and the US with over 400 employees. More information is available at [www.valneva.com](http://www.valneva.com).

Contacts:

Laetitia Bachelot-Fontaine  
Head of Investor Relations  
& Corporate Communications  
T +02-28-07-14-19  
M +33 (0)6 4516 7099

Nina Waibel  
Corporate Communications Specialist  
T +43-1-206 20-1116  
M +43-676-84 55 67 357  
[communications@valneva.com](mailto:communications@valneva.com)